Joseph T Coyle

List of Publications by Year
in descending order

305 papers	38,828 citations	4351 88 h-index	2872 190 g-index
326 all docs	326 docs citations	326 times ranked	22908 citing authors

#	Article	IF	Citations
1	Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology, 1981, 10, 122-126.	5.8	1,706
2	Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature, 1976, 263, 244-246.	36.2	1,248
3	Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron, 1989, 2, 1547-1558.	8.0	950
4	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences, 2008, 31, 234-242.	8.8	914
5	The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia. American Journal of Psychiatry, 2001, 158, 1367-1377.	8.7	843
6	Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. Cellular and Molecular Neurobiology, 2006, 26, 363-382.	3.3	788
7	Neurobiology of Schizophrenia. Neuron, 2006, 52, 139-153.	8.0	624
8	Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Annals of Neurology, 1990, 28, 18-25.	5.8	607
9	In situ injection of kainic acid: A new method for selectively lesioning neuronal cell bodies while sparing axons of passage. Journal of Comparative Neurology, 1978, 180, 301-323.	2.0	594
10	D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 1998, 44, 1081-1089.	1.3	590
11	Glutamatergic Mechanisms in Schizophrenia. Annual Review of Pharmacology and Toxicology, 2002, 42, 165-179.	9.6	571
12	Neurochemical aspects of the ontogenesis of cholinergic neurons in the rat brain. Brain Research, 1976, 118, 429-440.	2.3	561
13	Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Research, 1986, 371, 146-151.	2.3	541
14	The Glutamatergic Dysfunction Hypothesis for Schizophrenia. Harvard Review of Psychiatry, 1996, 3, 241-253.	2.2	530
15	Striatal lesions with kainic acid: neurochemical characteristics. Brain Research, 1977, 127, 235-249.	2.3	458
16	Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. Journal of Comparative Neurology, 1983, 217, 103-121.	2.0	456
17	A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia. Archives of General Psychiatry, 1999, 56, 21.	13.2	412
18	Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature, 1978, 271, 766-768.	36.2	405

#	Article	IF	Citations
19	Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB Journal, 1990, 4, 1624-1633.	0.5	399
20	N -Acetylaspartate in neuropsychiatric disorders. Progress in Neurobiology, 1995, 46, 531-540.	5.8	398
21	The Role of Glutamatergic Neurotransmission in the Pathophysiology of Alcoholism. Annual Review of Medicine, 1998, 49, 173-184.	12.2	383
22	Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments. Neuron, 2003, 38, 157-160.	8.0	356
23	N-Acetyl-Aspartyl-Glutamate: Regional Levels in Rat Brain and the Effects of Brain Lesions as Determined by a New HPLC Method. Journal of Neurochemistry, 1984, 43, 1136-1142.	4.0	352
24	NMDA Receptor and Schizophrenia: A Brief History. Schizophrenia Bulletin, 2012, 38, 920-926.	4.6	346
25	Prefrontal Cortical Dendritic Spine Pathology in Schizophrenia and Bipolar Disorder. JAMA Psychiatry, 2014, 71, 1323.	11.4	323
26	Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimerâ€™s disease. Biological Psychiatry, 2001, 49, 289-299.	1.3	321
27	Tyrosine hydroxylase in rat brainâ€"cofactor requirements, regional and subcellular distribution. Biochemical Pharmacology, 1972, 21, 1935-1944.	4.6	305
28	Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Molecular Psychiatry, 2017, 22, 936-943.	8.2	297
29	Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature, 1982, 298, 757-759.	36.2	286
30	Memory impairments following basal forebrain lesions. Brain Research, 1985, 346, 8-14.	2.3	257
31	Glutamate hypothesis in schizophrenia. Psychiatry and Clinical Neurosciences, 2019, 73, 204-215.	2.3	255
32	The distribution and orientation of noradrenergic fibers in neocortex of the rat: An immunofluorescence study. Journal of Comparative Neurology, 1978, 181, 17-39.	2.0	245
33	Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia. American Journal of Psychiatry, 1998, 155, 1207-1213.	8.7	236
34	Influence of cortico-striatal afferents on striatal kainic acid neurotoxicity. Neuroscience Letters, 1978, 8, 303-310.	2.1	215
35	The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology, 2004, 174, 32-8.	3.1	201
36	Histological and neurochemical effects of fetal treatment with methylazoxymethanol on rat neocortex in adulthood. Brain Research, 1979, 170, 135-155.	2.3	198

#	Article	IF	Citations
37	The Role of Brain Dopamine in Behavioral Regulation and the Actions of Psychotropic Drugs. American Journal of Psychiatry, 1970, 127, 199-207.	8.7	196
38	Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8485-8490.	7.6	193
39	Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2400-9.	7.6	190
40	Dopaminergic dysfunction in tourette syndrome. Annals of Neurology, 1982, 12, 361-366.	5.8	184
41	The differential effect of right versus left hemispheric cerebral infarction on catecholamines and behavior in the rat. Brain Research, 1980, 188, 63-78.	2.3	183
42	The NMDA receptor â€˜glycine modulatory siteâ€™ in schizophrenia: d-serine, glycine, and beyond. Current Opinion in Pharmacology, 2015, 20, 109-115.	3.6	178
43	Structure-activity relations for the neurotoxicity of kainic acid derivatives and glutamate analogues. Neuropharmacology, 1978, 17, 145-151.	4.2	175
44	The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochemical Pharmacology, 2004, 68, 1507-1514.	4.6	173
45	The Rise and Fall of the d -Serine-Mediated Gliotransmission Hypothesis. Trends in Neurosciences, 2016, 39, 712-721.	8.8	166
46	The Nagging Question of the Function ofN-Acetylaspartylglutamate. Neurobiology of Disease, 1997, 4, 231-238.	4.5	163
47	Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications. Handbook of Experimental Pharmacology, 2012, , 267-295.	0.0	153
48	Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs. Journal of Neuroscience, 2000, 20, 4011-4020.	3.8	149
49	Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neuroscience and Biobehavioral Reviews, 2011, 35, 848-870.	6.6	148
50	Biochemical Aspects of Neurotransmission in the Developing Brain. International Review of Neurobiology, 1977, 20, 65-103.	1.8	147
51	Neurochemical sequelae of kainate injections in corpus striatum and substantia nigra of the rat. Life Sciences, 1977, 20, 431-436.	4.4	143
52	Low Cerebrospinal Fluid Glutamate and Glycine in Refractory Affective Disorder. Biological Psychiatry, 2007, 61, 162-166.	1.3	140
53	Platelet serotonin, a possible marker for familial autism. Journal of Autism and Developmental Disorders, 1991, 21, 51-59.	3.1	134
54	Cell Selective Conditional Null Mutations of Serine Racemase Demonstrate a Predominate Localization in Cortical Glutamatergic Neurons. Cellular and Molecular Neurobiology, 2012, 32, 613-624.	3.3	132

#	Article	IF	Citations
55	Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4462-E4471.	7.6	132
56	Anatomical predictors of behavioral recovery following fetal striatal transplants. Brain Research, 1986, 365, 249-258.	2.3	127
57	DOPA decarâ˘ylase in the developing rat brain. Brain Research, 1972, 41, 503-506.	2.3	123
58	Rotational behaviour in rats with unilateral striatal kainic acid lesions: A behavioural model for studies on intact dopamine receptors. Brain Research, 1979, 170, 485-495.	2.3	120
59	NMDA Receptor Function, Neuroplasticity, and the Pathophysiology of Schizophrenia. International Review of Neurobiology, 2004, 59, 491-515.	1.8	116
60	Ontogeny of Neurochemical Markers for Noradrenergic, GABAergic and Cholinergic Neurons in Neocortex Lesioned with Methylazoxymethanol Acetate. Journal of Neurochemistry, 1980, 34, 1429-1441.	4.0	113
61	Basal forebrain lesions produce a dissociation of trial-dependent and trial-independent memory performance. Brain Research, 1985, 345, 315-321.	2.3	113
62	Inhibition of [3H]kainic acid receptor binding by divalent cations correlates with ion affinity for the calcium channel. Neuropharmacology, 1987, 26, 1247-1251.	4.2	111
63	d-Serine and Serine Racemase are Localized to Neurons in the Adult Mouse and Human Forebrain. Cellular and Molecular Neurobiology, 2014, 34, 419-435.	3.3	109
64	Mind Glue. Archives of General Psychiatry, 2000, 57, 90.	13.2	108
65	Uptake and Subcellular Localization of Neurotransmitters in the Brain. International Review of Neurobiology, 1970, 13, 127-158.	1.8	107
66	Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum. Journal of Neuroscience Research, 1979, 4, 383-398.	3.0	106
67	Reductions in acidic amino acids andN-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Research, 1991, 556, 151-156.	2.3	106
68	Characterization of specific, high-affinity binding sites for l-[3H]glutamic acid in rat brain membranes. Brain Research, 1980, 183, 421-433.	2.3	105
69	Enhanced astrocytic d-serine underlies synaptic damage after traumatic brain injury. Journal of Clinical Investigation, 2017, 127, 3114-3125.	8.2	104
70	Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. Journal of Comparative Neurology, 1999, 415, 52-64.	2.0	103
71	Cholinergic innervation of mouse forebrain structures. Journal of Comparative Neurology, 1994, 341, 117-129.	2.0	102
72	Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granule cells. Brain Research, 1993, 624, 223-232.	2.3	101

#	Article	IF	Citations
73	Folylpoly-Î³-glutamate Carboxypeptidase from Pig Jejunum. Journal of Biological Chemistry, 1998, 273, 20417-20424.	3.5	101
74	Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse, 1987, 1, 455-460.	1.3	99
75	Characterization of [3H]hemicholinium-3 binding associated with neuronal choline uptake sites in rat brain membranes. Brain Research, 1985, 348, 321-330.	2.3	98
76	Local and Distant Neuronal Degeneration Following Intrastriatal Injection of Kainic Acid. Journal of Neuropathology and Experimental Neurology, 1980, 39, 245-264.	1.8	97
77	Excitatory amino acids in amyotrophic lateral sclerosis: An update. Annals of Neurology, 1991, 30, 224-225.	5.8	95
78	Striatal opiate receptors: Pre- and postsynaptic localization. Life Sciences, 1980, 27, 1175-1183.	4.4	94
79	Serine Racemase Deletion Protects Against Cerebral Ischemia and Excitotoxicity. Journal of Neuroscience, 2010, 30, 1413-1416.	3.8	94
80	Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics. Psychopharmacology, 1981, 75, 9-15.	3.1	91
81	Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated ?-linked acidic dipeptidase (NAALADase). Journal of Comparative Neurology, 1992, 315, 217-229.	2.0	91
82	Down syndrome, Alzheimer's disease and the trisomy 16 mouse. Trends in Neurosciences, 1988, 11, 390-394.	8.8	88
83	Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cellâ€"derived cortical interneurons from subjects with schizophrenia. Nature Neuroscience, 2019, 22, 229-242.	14.5	88
84	Cortical Degeneration with Swollen Chromatolytic Neurons. Journal of Neuropathology and Experimental Neurology, 1986, 45, 268-284.	1.8	84
85	The Neurobiology of N-Acetylasparty. International Review of Neurobiology, 1988, , 39-100.	1.8	84
86	Psychotropic Drug Use in Very Young Children. JAMA - Journal of the American Medical Association, 2000, 283, 1059.	7.0	84
87	Calcium-dependent glutamate cytotoxicity in a neuronal cell line. Brain Research, 1988, 444, 325-332.	2.3	83
88	Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse, 2000, 36, 57-65.	1.3	82
89	The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiology of Disease, 2012, 45, 671-682.	4.5	82
90	Hydrolysis of the Brain Dipeptide N-Acetyl-l-Aspartyl-l-Glutamate: Subcellular and Regional Distribution, Ontogeny, and the Effect of Lesions on N-Acetylated-?-Linked Acidic Dipeptidase Activity. Journal of Neurochemistry, 1988, 50, 1200-1209.	4.0	79

#	Article	IF	Citations
91	Long-term sequelae of striatal kainate lesion. Brain Research, 1978, 152, 626-632.	2.3	78
92	The immunohistochemical demonstration of noradrenergic neurons in the rat brain: The use of homologous antiserum to dopamine-Î²-hydroxylase. Neuroscience Letters, 1977, 4, 127-134.	2.1	76
93	Decreased Cortical Glucose Utilization after Ibotenate Lesion of the Rat Ventromedial Globus Pallidus. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 381-390.	4.6	76
94	The Potential for Muscarinic Receptor Subtype-Specific Pharmacotherapy for Alzheimer's Disease. Mayo Clinic Proceedings, 1991, 66, 1225-1237.	2.8	76
95	Enhanced NAD(P)H:Quinone Reductase Activity Prevents Glutamate Toxicity Produced by Oxidative Stress. Journal of Neurochemistry, 1991, 56, 990-995.	4.0	76
96	A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacology Biochemistry and Behavior, 1988, 31, 141-147.	2.8	75
97	Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level. Nature Communications, 2013, 4, 1760.	13.2	75
98	Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology, 1990, 102, 191-200.	3.1	74
99	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biological Psychiatry, 1998, 44, 667-674.	1.3	73
100	Use It or Lose It â€" Do Effortful Mental Activities Protect against Dementia?. New England Journal of Medicine, 2003, 348, 2489-2490.	30.1	73
101	Phylogenetic distribution of [3H]kainic acid receptor binding sites in neuronal tissue. Brain Research, 1980, 192, 463-476.	2.3	70
102	Primary Degenerative Dementia Without Alzheimer Pathology. Canadian Journal of Neurological Sciences, 1986, 13, 462-470.	0.6	70
103	Glutamate Neurotoxicity and the Inhibition of Protein Synthesis in the Hippocampal Slice. Journal of Neurochemistry, 1991, 56, 996-1006.	4.0	69
104	Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. Neurotoxicity Research, 2006, 10, 221-233.	2.7	69
105	Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type. Annals of Neurology, 1985, 17, 46-48.	5.8	68
106	Ube3a mRNA and protein expression are not decreased in Mecp2 mutant mice. Brain Research, 2007, 1180, 1-6.	2.3	68
107	Calcium-Dependent Evoked Release of N[3H]Acetylaspartylglutamate from the Optic Pathway. Journal of Neurochemistry, 1988, 51, 1956-1959.	4.0	67
108	Developmental expression of somatostatin in mouse brain. II. In situ hybridization. Developmental Brain Research, 1990, 53, 26-39.	1.8	66

#	Article	IF	Citations
109	Cytotoxic lesions and the development of transmitter systems. Trends in Neurosciences, 1982, 5, 153-156.	8.8	65
110	N-acetylaspartylglutamate,N-acetylaspartate, andN-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer diseases. Molecular and Chemical Neuropathology, 1997, 31, 97-118.	1.0	64
111	Do Maternal Folate and Homocysteine Levels Play a Role in Neurodevelopmental Processes That Increase Risk for Schizophrenia?. Harvard Review of Psychiatry, 2005, 13, 197-205.	2.2	64
112	Selective immunocytochemical staining of mitral cells in rat olfactory bulb with affinity purified antibodies against N-acetyl-aspartyl-glutamate. Brain Research, 1987, 402, 373-378.	2.3	63
113	Developmental expression of somatostatin in mouse brain. I. Immunocytochemical studies. Developmental Brain Research, 1990, 53, 6-25.	1.8	63
114	Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues in Clinical Neuroscience, 2010, 12, 359-382.	4.7	63
115	Somatostatin is not co-localized in cholinergic neurons innervating the rat cerebral cortex-hippocampal formation. Brain Research, 1982, 243, 169-172.	2.3	62
116	Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice. Pharmacology Biochemistry and Behavior, 1989, 34, 129-137.	2.8	62
117	An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Neuropsychopharmacology, 2016, 41, 2052-2061.	5.6	61
118	NAAG Reduces NMDA Receptor Current in CA1 Hippocampal Pyramidal Neurons of Acute Slices and Dissociated Neurons. Neuropsychopharmacology, 2005, 30, 7-16.	5.6	60
119	Rapid regulation of [3H]hemicholinium-3 binding sites in the rat brain. Brain Research, 1986, 381, 191-194.	2.3	58
120	Noradrenergic innervation patterns in three regions of medial cortex: An immunofluorescence characterization. Brain Research Bulletin, 1979, 4, 849-857.	3.1	57
121	Site-Directed Mutagenesis of Predicted Active Site Residues in Glutamate Carboxypeptidase II. Molecular Pharmacology, 1999, 55, 179-185.	2.3	57
122	iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. Molecular Psychiatry, 2020, 25, 2873-2888.	8.2	57
123	N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. Journal of Neurocytology, 1995, 24, 99-109.	1.4	56
124	Regional heterogeneity of choline acetyltransferase activity in primate neocortex. Brain Research, 1984, 322, 361-364.	2.3	54
125	Lateralization of catecholaminergic and behavioral response to cerebral infarction in the rat. Life Sciences, 1979, 24, 943-950.	4.4	53
126	Basal forebrain neurons provide major cholinergic innervation of primate neocortex. Neuroscience Letters, 1986, 66, 215-220.	2.1	53

#	Article	IF	Citations
127	Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease. Neurobiology of Disease, 2019, 130, 104511.	4.5	53
128	Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia. Nature Neuroscience, 2020, 23, 1352-1364.	14.5	53
129	Head and trunk neural crest in vitro: Autonomic neuron differentiation. Developmental Biology, 1980, 77, 340-348.	2.1	52
130	Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. Brain Research, 1998, 789, 32-39.	2.3	51
131	Treating a Child With Aspergerâ€™s Disorder and Comorbid Bipolar Disorder. American Journal of Psychiatry, 2002, 159, 13-21.	8.7	50
132	Inhibitors of GABA metabolism: Implications for Huntington's disease. Annals of Neurology, 1977, 2, 299-303.	5.8	49
133	Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Research, 1998, 795, 341-348.	2.3	49
134	The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. Neuroscience Letters, 1989, 100, 295-300.	2.1	48
135	Effects of Kainic Acid on High-Energy Metabolites in the Mouse Striatum. Journal of Neurochemistry, 1982, 38, 196-203.	4.0	47
136	Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. Journal of Physiology, 2005, 563, 777-793.	2.9	46
137	Astroglial Versus Neuronal D-Serine: Check Your Controls!. Trends in Neurosciences, 2017, 40, 520-522.	8.8	46
138	Astrocytes in primary cultures express serine racemase, synthesize d -serine and acquire A1 reactive astrocyte features. Biochemical Pharmacology, 2018, 151, 245-251.	4.6	46
139	Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse. American Journal of Psychiatry, 2020, 177, 1119-1128.	8.7	46
140	Dissociation of nitric oxide generation and kainate-mediated neuronal degeneration in primary cultures of rat cerebellar granule cells. Neuropharmacology, 1992, 31, 565-575.	4.2	45
141	Glutamate Carboxypeptidase II Gene Expression in the Human Frontal and Temporal Lobe in Schizophrenia. Neuropsychopharmacology, 2004, 29, 117-125.	5.6	45
142	Age-related recurrence of basal forebrain lesion-induced cholinergic deficits. Neuroscience Letters, 1987, 82, 253-259.	2.1	44
143	Neuronal d-serine regulates dendritic architecture in the somatosensory cortex. Neuroscience Letters, 2012, 517, 77-81.	2.1	44
144	Enhancement of NMDA receptor-mediated neurotoxicity in the hippocampal slice by depolarization and ischemia. Brain Research, 1991, 555, 99-106.	2.3	43

#	Article	IF	Citations
145	Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of d-cycloserine. Psychiatry Research - Neuroimaging, 2005, 138, 23-31.	1.9	43
146	Developmental regulation of adult cortical morphology and behavior: An animal model for mental retardation. International Journal of Developmental Neuroscience, 1994, 12, 239-253.	1.6	42
147	Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Research, 1997, 772, 9-22.	2.3	42
148	Synaptosomal Transport of Radiolabel from <i>N</i>â€Acetylâ€Aspartylâ€[³H]Glutamate Suggests a Mechanism of Inactivation of an Excitatory Neuropeptide. Journal of Neurochemistry, 1986, 47, 1013-1019.	4.0	42
149	NAAG, NMDA Receptor and Psychosis. Current Medicinal Chemistry, 2012, 19, 1360-1364.	2.5	41
150	History of the Concept of Disconnectivity in Schizophrenia. Harvard Review of Psychiatry, 2016, 24, 80-86.	2.2	41
151	Avoidance conditioning in different strains of rats: Neurochemical correlates. Psychopharmacology, 1973, 31, 25-34.	3.1	40
152	Subcellular localization of dopamine Î2-hydroxylase and endogenous norepinephrine in the rat hypothalamus. Brain Research, 1974, 65, 475-487.	2.3	40
153	Evoked release of aspartate and glutamate: disparities between prelabeling and direct measurement. Brain Research, 1983, 278, 279-282.	2.3	40
154	Quisqualate selectively inhibits a brain peptisade which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. European Journal of Pharmacology, 1986, 130, 345-347.	3.6	40
155	Lesions of the basal forebrain alter stimulus-evoked metabolic activity in mouse somatosensory cortex. Journal of Comparative Neurology, 1989, 288, 414-427.	2.0	40
156	d-Serine, the Shape-Shifting NMDA Receptor Co-agonist. Neurochemical Research, 2020, 45, 1344-1353.	3.3	40
157	Brain Serotonin2and Serotonin1AReceptors Are Altered in the Congenitally Hyperammonemic Sparse Fur Mouse. Journal of Neurochemistry, 1992, 58, 1016-1022.	4.0	39
158	The Role of Serine Racemase in the Pathophysiology of Brain Disorders. Advances in Pharmacology, 2018, 82, 35-56.	3.4	39
159	Neuronal localization of specific brain phosphoproteins. Brain Research, 1978, 156, 345-350.	2.3	38
160	Anorexia and altered serotonin metabolism in a patient with argininosuccinic aciduria. Journal of Pediatrics, 1986, 108, 705-709.	2.2	38
161	Behavioral and Neurotransmitter Changes in the Urease-Infused Rat: A Model of Congenital Hyperammonemia. Pediatric Research, 1986, 20, 1310-1315.	2.4	38
162	Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. Brain Research, 1992, 593, 140-143.	2.3	37

#	Article	IF	Citations
163	Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. Journal of Neurochemistry, 2007, 100, 346-357.	4.0	37
164	Chronic D-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochemistry International, 2014, 75, 76-78.	3.9	37
165	Alterations of muscarinic cholinergic receprtors in the rat striatum after kainic acid injections. Brain Research, 1978, 152, 620-625.	2.3	36
166	L-type voltage-gated calcium channels modulate kainic acid neurotoxicity in cerebellar granule cells. Brain Research, 1999, 828, 27-40.	2.3	36
167	Automated measurement of stereotypic behavior in rats.. Behavioral Neuroscience, 1983, 97, 830-832.	1.2	35
168	Quantitation of N-acetyl-aspartyl-glutamate in microdissected rat brain nuclei and peripheral tissues: findings with a novel liquid phase radioimmunoassay. Molecular Brain Research, 1988, 3, 223-231.	2.4	35
169	Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biological Psychiatry, 2019, 86, 523-535.	1.3	35
170	Rapid axonal transport of tyroxine hydroxylase and dopamine-Î²-hydroxylase. Brain Research, 1972, 44, 701-704.	2.3	34
171	Effect of Sodium Benzoate and Sodium Phenylacetate on Brain Serotonin Turnover in the Ornithine Transcarbamylase-Deficient Sparse-Fur Mouse. Pediatric Research, 1988, 23, 368-374.	2.4	34
172	N-Acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neuroscience Letters, 1997, 236, 91-94.	2.1	34
173	The Role of Animal Models in Evaluating Reasonable Safety and Efficacy for Human Trials of Cell-Based Interventions for Neurologic Conditions. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1-9.	4.6	34
174	InÂVivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Timeâ€"Averaged Proton Magnetic Resonance Spectroscopy at 4T. Biological Psychiatry, 2018, 83, 484-491.	1.3	34
175	Dopaminergic neurons in explants of substantia nigra in culture. Journal of Neurobiology, 1973, 4, 461-470.	3.1	33
176	Cerebrospinal Fluid Correlates of Depression in Huntington's Disease. Archives of Neurology, 1988, 45, 881-883.	4.5	33
177	Serine Racemase and D-serine in the Amygdala Are Dynamically Involved in Fear Learning. Biological Psychiatry, 2018, 83, 273-283.	1.3	33
178	Postsynaptic Serine Racemase Regulates NMDA Receptor Function. Journal of Neuroscience, 2020, 40, 9564-9575.	3.8	33
179	Pharmacological augmentation of acetylcholine levels in kainate-lesioned rat striatum. Biochemical Pharmacology, 1978, 27, 2962-2965.	4.6	32
180	Immunocytochemical distribution of n-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. Journal of Chemical Neuroanatomy, 1993, 6, 277-292.	2.2	32

#	Article	IF	Citations
181	Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction. Brain Research, 2011, 1392, 1-7.	2.3	32
182	Suspected Adverse Methylphenidate-Imipramine Interactions in Children. Journal of Developmental and Behavioral Pediatrics, 1986, 7, 265-267.	1.2	31
183	EphB3 signaling propagates synaptic dysfunction in the traumatic injured brain. Neurobiology of Disease, 2016, 94, 73-84.	4.5	30
184	Schizophrenia: Basic and Clinical. Advances in Neurobiology, 2017, 15, 255-280.	0.0	30
185	Excitatory amino acid analogs evoke release of endogenous amino acids and acetyl choline from chick retina in vitro. Vision Research, 1985, 25, 1375-1386.	1.5	29
186	Regional brain levels of N-acetyl-aspartyl-glutamate: the effect of kindled seizures. Brain Research, 1985, 346, 392-396.	2.3	29
187	Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. Neuroscience Letters, 2011, 488, 267-271.	2.1	29
188	Effects of intrastriatal injections of the cholinergic neurotoxin AF64A on spontaneous nocturnal locomotor behavior in the rat. Brain Research, 1984, 299, 339-343.	2.3	28
189	Developmental consequences of autosomal aneuploidy in mammals. Genesis, 1987, 8, 249-265.	2.6	28
190	Getting balance: Drugs for bipolar disorder share target. Nature Medicine, 2002, 8, 557-558.	30.1	28
191	Beyond In Vitro Data: A Review of In Vivo Evidence Regarding the Allosteric Potentiating Effect of Galantamine on Nicotinic Acetylcholine Receptors in Alzheimer's Neuropathology. Journal of Alzheimer's Disease, 2007, 11, 491-507.	2.7	28
192	Altered prefrontal cortical MARCKS and PPP1R9A mRNA expression in schizophrenia and bipolar disorder. Schizophrenia Research, 2015, 164, 100-108.	2.1	28
193	In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia. Neurobiology of Disease, 2015, 73, 269-274.	4.5	28
194	MicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2975-2976.	7.6	27
195	N-methyl-d-aspartic acid: A convulsant with weak neurotoxic properties. Neuroscience Letters, 1981, 24, 181-186.	2.1	26
196	Investigating brain <scp>d</scp>â€serine: Advocacy for good practices. Acta Physiologica, 2019, 226, e13257.	3.9	26
197	Kainic Acid: Insights into Excitatory Mechanisms Causing Selective Neuronal Degeneration. Novartis Foundation Symposium, 1987, 126, 186-203.	0.0	26
198	The development of catecholaminergic innervation in chick spinal cord. Brain Research, 1980, 191, 417-428.	2.3	25

#	Article	IF	Citations
199	Regulation of Glutamate Carboxypeptidase II Function in Corticolimbic Regions of Rat Brain by Phencyclidine, Haloperidol, and Clozapine. Neuropsychopharmacology, 2003, 28, 1227-1234.	5.6	25
200	Decoding Schizophrenia. Scientific American, 2004, 290, 48-55.	0.0	25
201	Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse, 2009, 63, 625-635.	1.3	25
202	Neuronal serine racemase regulates extracellular d-serine levels in the adult mouse hippocampus. Journal of Neural Transmission, 2015, 122, 1099-1103.	2.9	25
203	Solubilization and Characterization of a [3H]Hemicholinium-3 Binding Site in Rat Brain. Journal of Neurochemistry, 1988, 50, 1759-1764.	4.0	24
204	Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2382-2387.	3.8	24
205	Parametric influences on catalepsy. Psychopharmacology, 1984, 82, 406-408.	3.1	23
206	Development of Î²1 and Î²2 adrenergic receptors in baboon brain: An autoradiographic study using [125I]iodocyanopindolol. Journal of Comparative Neurology, 1988, 273, 318-329.	2.0	23
207	Long-term effects of basal forebrain lesions on cholinergic, noradrenergic and serotonergic markers in mouse neocortex. Brain Research Bulletin, 1988, 21, 13-20.	3.1	22
208	Development of Central Neurotransmitter Systems. Novartis Foundation Symposium, 1981, 86, 251-270.	0.0	22
209	The role of calcium in the regulation of [3H]hemicholinium-3 binding sites in rat brain. Neuropharmacology, 1988, 27, 1301-1308.	4.2	21
210	Involvement of phospholipase A2 in the regulation of [3H]hemicholinium-3 binding. Biochemical Pharmacology, 1988, 37, 4367-4373.	4.6	20
211	Seizures decrease regional enzymatic hydrolysis of N-acetyl-aspartylglutamate in rat brain. Brain Research, 1989, 505, 130-134.	2.3	20
212	Drug Treatment of Anxiety Disorders in Children. New England Journal of Medicine, 2001, 344, 1326-1327.	30.1	20
213	Serine racemase deletion abolishes lightâ€evoked NMDA receptor currents in retinal ganglion cells. Journal of Physiology, 2011, 589, 5997-6006.	2.9	20
214	Altered Acquisition and Extinction of Amphetamine-Paired Context Conditioning in Genetic Mouse Models of Altered NMDA Receptor Function. Neuropsychopharmacology, 2012, 37, 2496-2504.	5.6	20
215	Touchscreen assays of learning, response inhibition, and motivation in the marmoset (Callithrix) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.8	20
216	Neurotoxic amino acids in human degenerative disorders. Trends in Neurosciences, 1982, 5, 287-288.	8.8	19

#	Article	IF	Citations
217	Global Biochemical Profiling Identifies Î²-Hydroxypyruvate as a Potential Mediator of Type 2 Diabetes in Mice and Humans. Diabetes, 2015, 64, 1383-1394.	0.9	19
218	<i>N</i>â€Methylâ€<scp>d</scp>â€aspartate receptor coâ€agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. Addiction Biology, 2019, 24, 40-50.	2.7	19
219	Neuroleptic Drug Level Monitoring in Psychiatry. Therapeutic Drug Monitoring, 1982, 4, 59-64.	2.2	18
220	Serum neuroleptic concentrations and clinical response: A radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology, 1984, 82, 194-198.	3.1	18
221	Investigating locomotion abnormalities in animal models of extrapyramidal disorders: A commentary. Physiological Psychology, 1984, 12, 48-50.	0.7	18
222	The dissociation of evoked release of [3H]-GABA and of endogenous GABA from chick retina in vitro. Experimental Eye Research, 1984, 39, 299-305.	2.7	18
223	Neurochemical characterization of embryonic brain development in trisomy 19 (Ts19) mice: Implications of selective deficits observed for abnormal neural development in aneuploidy. Genesis, 1987, 8, 267-279.	2.6	18
224	The glycine transporter GlyT1 controls<i>N</i>â€methylâ€Dâ€aspartic acid receptor coagonist occupancy in the mouse retina. European Journal of Neuroscience, 2009, 30, 2308-2317.	3.5	18
225	Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia. Schizophrenia Research, 2018, 201, 270-277.	2.1	18
226	Adenylate cyclase activity in chick retina. General Pharmacology, 1976, 7, 349-354.	0.6	17
227	Kainic acid lesion of mouse striatum: Effects on energy metabolites. Life Sciences, 1980, 27, 2495-2500.	4.4	17
228	What can a clock mutation in mice tell us about bipolar disorder?. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6097-6098.	7.6	17
229	Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: Implications for neurodevelopmental disorders. Developmental Neurobiology, 2012, 72, 891-905.	3.1	17
230	Absence of a relationship between sympathetic neuronal activity and turnover of serum dopamine-?-hydroxylase. Naunyn-Schmiedeberg's Archives of Pharmacology, 1978, 304, 231-236.	3.1	16
231	Synaptic Chemistry Associated with Aberrant Neuronal Development in the Reeler Mouse. Journal of Neurochemistry, 1983, 41, 874-881.	4.0	16
232	Availability of <i>N</i>-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 465-470.	2.4	16
233	Altered neural oscillations and behavior in a genetic mouse model of NMDA receptor hypofunction. Scientific Reports, 2021, 11, 9031.	3.4	16
234	Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist <scp>d</scp> -serine. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.6	16

#	Article	IF	Citations
235	Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. Psychopharmacology, 2013, 230, 57-67.	3.1	15
236	Nitric Oxide and Symptom Reduction in Schizophrenia. JAMA Psychiatry, 2013, 70, 664.	11.4	15
237	Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. Brain Research, 1993, 629, 305-309.	2.3	14
238	Neuronal mapping with kainic acid. Trends in Neurosciences, 1978, 1, 132-135.	8.8	13
239	Neurotransmitter specific alterations in dementing disorders: Insights from animal models. Journal of Psychiatric Research, 1984, 18, 501-512.	3.2	13
240	A re-examination of the interaction of N-acetyl-L-aspartyl-L-glutamate with a subpopulation of rat brain membrane L-[3H]glutamate binding sites. European Journal of Pharmacology, 1988, 151, 419-426.	3.6	13
241	Insulin-Like Growth Factor I Prevents the Development of Sensitivity to Kainate Neurotoxicity in Cerebellar Granule Cells. Journal of Neurochemistry, 2002, 75, 1548-1556.	4.0	13
242	Glial metabolites of tryptophan and excitotoxicity: Coming unglued. Experimental Neurology, 2006, 197, 4-7.	4.1	13
243	Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. Psychopharmacology, 2011, 213, 143-153.	3.1	13
244	Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice. Schizophrenia Research, 2015, 162, 216-221.	2.1	13
245	Specific alterations in the levels of N-acetyl-aspartyl-glutamate in the nervous system of the dystrophic mouse. Neuroscience Letters, 1987, 79, 223-228.	2.1	12
246	Developmental expression of the gene encoding growth-associated protein 43(GAP43) in the brains of normal and aneuploid mice. Journal of Neuroscience Research, 1991, 29, 449-460.	3.0	12
247	Effects of overexpression of the cytoplasmic copper-zinc superoxide dismutase on the survival of neurons in vitro. Synapse, 1998, 29, 206-212.	1.3	12
248	L-type calcium channels reduce ROS generation in cerebellar granule cells following kainate exposure. Synapse, 2002, 43, 30-41.	1.3	12
249	Synaptic Neurochemical Alterations Associated with Neuronal Degeneration in an Inherited Cerebellar Ataxia of Gordon Setters. Journal of Neuropathology and Experimental Neurology, 1984, 43, 580-591.	1.8	11
250	Increased number of somatostatin-immunoreactive neurons in primary cultures of Trisomy 16 mouse neocortex. Molecular Brain Research, 1990, 7, 269-272.	2.4	11
251	Effects of spinal transection on presynaptic markers for glutamatergic neurons in the rat. Neurochemical Research, 1981, 6, 485-496.	3.3	10
252	The postnatal expression of acetylcholinesterase in somatostatin-positive cells of mouse hippocampus. Developmental Brain Research, 1989, 48, 73-85.	1.8	10

#	Article	IF	Citations
253	Chapter 1: Same brain, new decade: Challenges in CNS drug discovery in the postgenomic, proteomic era. Annual Reports in Medicinal Chemistry, 2001, 36, 1-10.	0.8	10
254	Short-term and Long-term Effects of N-Methyl-D-Aspartate Receptor Hypofunction. Archives of General Psychiatry, 2000, 57, 1180.	13.2	10
255	Chapter 23 Transplantation of brain tissue from murine trisomy 16 into euploid hosts: Effects of gene imbalance on brain development. Progress in Brain Research, 1990, 82, 203-214.	3.9	9
256	The demise of old certitudes and the birth of novel opportunities in neuropsychopharmacology. Current Opinion in Pharmacology, 2004, 4, 1-3.	3.6	9
257	Combined Use of Tricyclic Antidepressants and Neuroleptics in the Management of Terminally 111 Children: A Report on Three Cases. Journal of the American Academy of Child Psychiatry, 1985, 24, 487-489.	0.7	8
258	Effects of calmodulin antagonists on sodium-dependent high-affinity choline uptake. Brain Research, 1991, 542, 132-134.	2.3	8
259	D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT2A receptor agonist DOI. Behavioural Brain Research, 2014, 259, 242-246.	2.3	7
260	Endogenous co-agonists of the NMDA receptor modulate contextual fear in trace conditioning. Neurobiology of Learning and Memory, 2016, 136, 244-250.	2.0	7
261	Clinical evidence that a dysregulated master neural network modulator may aid in diagnosing schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.6	7
262	Serine Racemase Expression by Striatal Neurons. Cellular and Molecular Neurobiology, 2022, 42, 279-289.	3.3	7
263	Impact of schizophrenia GWAS loci converge onto distinct pathways in cortical interneurons vs glutamatergic neurons during development. Molecular Psychiatry, 2022, 27, 4218-4233.	8.2	7
264	The Clinical Use of Antipsychotic Medications. Medical Clinics of North America, 1982, 66, 993-1009.	2.3	6
265	The Neuroscience Perspective and the Changing Role of the Psychiatrist. Academic Psychiatry, 1995, 19, 202-212.	0.7	6
266	Glutamate Carboxypeptidase II. , 2013, , 1620-1627.		6
267	Location matters: distinct DNA methylation patterns in GABAergic interneuronal populations from separate microcircuits within the human hippocampus. Human Molecular Genetics, 2018, 27, 254-265.	3.0	6
268	The Discovery and Characterization of Targeted Perikaryal-Specific Brain Lesions With Excitotoxins. Frontiers in Neuroscience, 2020, 14, 927.	2.9	6
269	The development of daytime rearing behavior in methylazoxymethanol-treated rats: Methodological considerations. Behavioural Brain Research, 1987, 25, 97-100.	2.3	5
270	Cortical Pyramidal Neurons Show a Selective Loss of New Synapses in Chronic Schizophrenia. American Journal of Psychiatry, 2017, 174, 510-511.	8.7	5

#	Article	IF	Citations
271	Electroretinographic Abnormalities and Sex Differences Detected with Mesopic Adaptation in a Mouse Model of Schizophrenia: A and B Wave Analysis. , 2020, 61, 16.		5
272	Promoter analysis of human glutamate carboxypeptidase II. Brain Research, 2007, 1170, 1-12.	2.3	4
273	Much More Than a Name Change. JAMA Psychiatry, 2013, 70, 8.	11.4	4
274	Glutamatergic Dysfunction in Schizophrenia Evaluated With Magnetic Resonance Spectroscopy. JAMA Psychiatry, 2016, 73, 649.	11.4	4
275	Psychiatric Drugs in Medical Practice. Medical Clinics of North America, 1977, 61, 891-905.	2.3	3
276	Mice Transgenic for Copper/Zinc Superoxide Dismutase Exhibit Increased Markers of Biogenic Amine Function. Journal of Neurochemistry, 2002, 65, 660-669.	4.0	3
277	d-Serine and the Pathophysiology of Schizophrenia. , 2016, , 101-118.		3
278	Factors regulating serine racemase and d-amino acid oxidase expression in the mouse striatum. Brain Research, 2021, 1751, 147202.	2.3	3
279	Kindling increases brain levels of NAAG and seizures reduce activity of a NAAG-hydrolyzing enzyme, NAALADase. , 1992, 8, 297-305.		3
280	<i>In Reply</i>: Neuroleptic Malignant Syndrome. Pediatrics, 1991, 88, 1074-1074.	2.2	3
281	Somatostatin expression in TS16 mouse brain cultures. Journal of Molecular Neuroscience, 1998, 10, 99-111.	2.4	2
282	Ice-Nine and Human Prion Disease. Harvard Review of Psychiatry, 1999, 6, 331-333.	2.2	2
283	Brain Structural Alterations Induced by Fetal Exposure to Cocaine Persist Into Adolescence and Affect Behavior. JAMA Psychiatry, 2013, 70, 1113.	11.4	2
284	Possible Compensatory Mechanisms for Glutamatergic Disconnection Found in the Auditory Cortex in Schizophrenia. Biological Psychiatry, 2015, 77, 923-924.	1.3	2
285	Altered CREB Binding to Activity-Dependent Genes in Serine Racemase Deficient Mice, a Mouse Model of Schizophrenia. ACS Chemical Neuroscience, 2018, 9, 2205-2209.	3.7	2
286	A Brief Overview of N-Acetylaspartate and N-Acetylaspartylglutamate. , 2006, 576, 1-6.		2
287	Topography of Locomotor Behaviour in the Chick. Bird Behavior, 1986, 6, 93-96.	0.2	1
288	Funding of NIMH extramural research. Science, 1994, 264, 1517-1517.	20.9	1

#	Article	IF	Citations
289	Science and Psychiatry: Groundbreaking Discoveries in Molecular Neuroscienceby Solomon H. Snyder, M.D. Arlington, Va, American Psychiatric Publishing, 2008, 513 pp., $65.00.. American Journal of Psychiatry, 2008, 165, 1492-1493.	8.7	1
290	Changes in JAMA and the Archives of General Psychiatry. Archives of General Psychiatry, 2012, 69, 447.	13.2	1
291	The Neurochemistry of Schizophrenia. , 2012, , 1000-1011.		1
292	Psychiatric Neuroscience: Incorporating Pathophysiology into Clinical Case Formulation. , 2008, , 543-564.		1
293	Glutamatergic Synaptic Dysregulation in Schizophrenia. , 2012, , 115-142.		1
294	Ontogenetic regulation of catecholamine synthesis. Life Sciences, 1973, 13, xxii-xxiii.	4.4	0
295	Neurotransmitter actions in the vertebrate nervous system. Cell, 1986, 45, 783.	27.8	0
296	Glutamate induced neuronal degeneration and oxidative stress. The Japanese Journal of Pharmacology, 1990, 52, 4.	1.2	0
297	The JAMA Network Journals. Archives of Neurology, 2012, 69, 817.	4.5	0
298	Section summary and perspectives: Translational medicine in psychiatry. , 0, , 118-128.		0
299	The discovery and development of drugs to treat psychiatric disorders: Historical perspective. , 0, , 1-13.		0
300	Relapse in Alcohol Use Disorderâ€"Reply. JAMA Psychiatry, 2013, 70, 1248.	11.4	0
301	Serine Racemase in Inhibitory Neurons at Striatum and it Might be Involved in Schizophrenia's Pathophysiology with d1 and d2 Receptors. European Psychiatry, 2016, 33, S467-S467.	0.2	0
302	In memoriamâ€"Alan Ivan Green, MD (1943â€"2020). Neuropsychopharmacology, 2021, 46, 1058-1059.	5.6	0
303	Glutamate carboxypeptidase II. , 2004, , 960-963.		0
304	Dona Lee Wong (1946â€"2022). Neuropsychopharmacology, 0, , .	5.6	0
305	Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia. Biochemical Pharmacology, 2024, , 116376.	4.6	0